Clinical Characteristics of Disseminated Strongyloidiasis, Japan, 1975-2017

Emerg Infect Dis. 2020 Mar;26(3):401-408. doi: 10.3201/eid2603.190571.

Abstract

Clinical characteristics of disseminated strongyloidiasis, the severest form of strongyloidiasis, are not well described. We conducted a retrospective, consecutive chart review of patients with disseminated strongyloidiasis admitted to Okinawa Chubu Hospital in Okinawa, Japan, during January 1975-December 2017. The 70 patients were classified into 3 clinical phenotypes: dissemination (32 patients [45.7%]), occult dissemination with meningitis caused by enteric organisms (12 patients [17.1%]), and occult dissemination with culture-negative suppurative meningitis (26 patients [37.1%]). Associated mortality rates were 56.3%, 16.7%, and 11.5%, respectively, and sepsis occurred in 40.6%, 58.3%, and 11.5% of cases, respectively. Common symptoms included fever (52.9% of patients), headache (32.9%), and altered mental status (24.3%). Patients were treated with thiabendazole (before 2003) or ivermectin (after 2003). Our findings show that disseminated strongyloidiasis has clinical phenotypes in terms of severity and that identification of occult dissemination, a mild form with prominent neurologic manifestations, is lifesaving.

Keywords: HTLV-1; Japan; Strongyloides stercoralis; dissemination; human T-cell lymphotrophic virus type 1; meningitis; nematodes; parasites; roundworms; strongyloidiasis.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anthelmintics / therapeutic use
  • Female
  • Humans
  • Ivermectin / therapeutic use
  • Japan / epidemiology
  • Male
  • Medical Records
  • Meningitis, Bacterial / drug therapy
  • Meningitis, Bacterial / epidemiology*
  • Meningitis, Bacterial / etiology
  • Middle Aged
  • Retrospective Studies
  • Strongyloidiasis / drug therapy
  • Strongyloidiasis / epidemiology*
  • Strongyloidiasis / etiology
  • Thiabendazole / therapeutic use
  • Young Adult

Substances

  • Anthelmintics
  • Ivermectin
  • Thiabendazole